Amarin Corp Plc (AMRN)

[isaeed]

Why I strongly believe AMR102 will become the future standard therapy for controlling Cholesterol. I will go further and boldly say that it will replace all statin treatments. Why? Read on.

This belief is based on facts and results from Anchor and COMBOS studies.

The COMBOS study was very similar to what the AMR 102 study is. Just instead of Vascepa, Lovaza was used in combination with a simvastatin. The study had 254 patients with TG levels 200-499 (Anchor). The results were amazing: 9% additional reduction in NON HDL-C and 9.6% additional reduction in total cholesterol (HDL-C) vs statins alone. Except for ONE drawback: net LDL-C went up by 0.7% whereas with statin alone it went down by 2.9%.

What does that mean for Vascepa? Vascepa's surprise quality (for which it is receiving the patents) is that it reduces LDL-C. Combine that with the LDL-C reducing capabilities of a statin, you get a fantastic result and reduction of all three markers: non HDL-C, Total cholesterol and most importantly LDL-C. This in addition to the reduction in the inflammatory markers which are probably the major cause of all diseases (not sure if there are any previous studies done to show this except maybe Jelis).

Results for AMR102 are due by end of May - June. The market will react big to this. And this will be a big positive for FDA to accept the sNDA for Anchor. if You think about it, the timing of the filing and expected results of AMR102 are all strategically done by JZ and team. It all makes sense to me.

This will be a major event for Amarin and a big win for cardiovascular therapy. A big money maker for whoever owns Amarin in the future. The market hasn’t even bothered to value this hidden gem (JMHO). I also believe that Vascepa alone will not be used for Anchor. It will be AMR102. This will potentially eat up markets of Lipitor and other standalone statins and may end up replacing all of these statins at some point in the future.

Just think why take Lipitor when a combination drug reduces all 3 markers more significantly than Lipitor alone.

(my mother, brother and father are all on statins which means that at some point I will be needing them as well, so I know how important this is for us).

I am a proud owner of AMRN since prior to approval and pray for AMARIN and team and wish them success.

Link for COMBOS results: http://www.medscape.org/viewarticle/564604